Clinical Trial

TUDCA as a Therapy for Ulcerative Colitis (UC)

Study Description

TUDCA as a Therapy for Ulcerative Colitis (UC)

This is a Phase I open label study examining the efficacy and safety of TUDCA (tauroursodeoxycholic acid) in ulcerative colitis treatment.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Tauroursoursodeoxycholic acid, brand name Tudcabil

Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day

Additional Information

Official Study Title

A Phase I Open Label Study of the Efficacy and Safety of Tudca in Ulcerative Colitis

Clinical Trial ID

NCT04114292

ParticipAid ID

erk3Ea